Director Buys 375,000 Shares, Eliminates Preferred Stock in Big Insider Move at Bambusa Therapeutics
Insider buying surge at Bambusa Therapeutics signals confidence in its bispecific antibody pipeline and a streamlined equity structure ahead of a potential IPO.
4 minutes to read